01—Abstract
Summary
Summary of the 10-Q filed July 29, 2024. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare's second quarter 2024 results showed continued top-line momentum.
Revenues rose 10.3% year over year to $17.492 billiona, driven by a 6.0% increase in equivalent admissions and a 4.1% increase in revenue per equivalent admission. Net income attributable to HCA grew 22.5% to $1.461 billion, and diluted EPS rose to $5.53 from $4.29. Results were helped by a $12 million gain on facility sales in the quarter, while the six-month period included a larger $213 million gain, primarily from the sale of a California hospital.
Operating margin pressure is visible in the cost lines: other operating expenses rose to 20.7% of revenue from 19.2%, driven by professional fees and state provider fees, while salaries and benefits improved to 43.9% of revenue from 45.9%, helped by a 25.7% decline in contract labor. Cash generation and balance sheet items warrant attention. Operating cash flow for the quarter fell $504 million year over year to $1.971 billionb, mainly because of a $824 million negative swing in working capital, chiefly higher accounts receivable and lower accounts payable.
Total debt rose to $40.880 billionc, and the current portion of long-term debt jumped to $4.574 billion, which pushed working capital down to $872 million from $2.272 billion at year-end 2023. HCA issued $4.5 billion of senior notes in February 2024 and repaid a $2.0 billion maturity in March. Capital spending remains heavy, with planned 2024 capex of $5.1 to $5.3 billion.
Management also returned significant capital to shareholders, repurchasing $2.547 billiond of stock in the first half and declaring a $0.66 quarterly dividend, while shares outstanding fell to 259.2 million from 265.5 million at year-end 2023. Overall, the filing reflects strong earnings growth supported by volume gains and labor cost relief, offset by rising non-labor costs, weaker working capital conversion, and a larger debt load. Investors would likely focus on whether accounts receivable trends normalize and whether the company can sustain margin improvement while funding elevated capital spending and buybacks.
02—Key points
Key Highlights
- Revenue grew 10.3% to $17.492 billion in Q2 2024, with equivalent admissions up 6.0% and revenue per equivalent admission up 4.1%; same facility revenue rose 9.9%.
- Net income attributable to HCA Healthcare was $1.461 billion ($5.53 diluted EPS) in Q2 2024, up 22.5% from $1.193 billion ($4.29) a year earlier.
- Salaries and benefits fell to 43.9% of revenue from 45.9%, aided by a 25.7% decline in contract labor, while other operating expenses rose to 20.7% of revenue from 19.2%.
- Operating cash flow for Q2 2024 declined $504 million to $1.971 billion, primarily from a $824 million negative working capital swing, mainly higher accounts receivable.
- Total debt reached $40.880 billion at June 30, 2024, and the current portion of long-term debt rose to $4.574 billion, reducing working capital to $872 million from $2.272 billion at year-end 2023.
- HCA repurchased $2.547 billion of common stock in the first six months of 2024 and reduced shares outstanding to 259.2 million; the Board declared a $0.66 quarterly dividend.
- Planned 2024 capital expenditures are $5.1 to $5.3 billion, and the company has about $4.6 billion of estimated remaining costs on projects under construction.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 29, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $17.49B$15.86B | +10.3% |
| Operating Expenses | $15.26B$14.05B | +8.6% |
| Interest Expense | $506.00M$485.00M | +4.3% |
| Net Income | $1.46B$1.19B | +22.5% |
| EPS (Basic) | $5.60$4.35 | +28.7% |
| EPS (Diluted) | $5.53$4.29 | +28.9% |
| Shares Outstanding (Basic) | 261.16M274.49M | −4.9% |
| Shares Outstanding (Diluted) | 264.07M278.20M | −5.1% |
05—Questions
Frequently Asked Questions
What drove HCA's revenue growth in the second quarter of 2024?
Revenue increased 10.3% to $17.492 billion, mainly from a 6.0% increase in equivalent admissions and a 4.1% increase in revenue per equivalent admission. Same facility revenue grew 9.9%. Inpatient admissions rose 6.0%, emergency department visits rose 5.3%, and outpatient surgeries declined 0.3%.
Why did operating cash flow decline even though net income grew?
Operating cash flow fell $504 million to $1.971 billion in Q2 2024. Management attributed this mainly to an $824 million negative swing in working capital, driven by higher accounts receivable and lower accounts payable, plus a $232 million increase in income tax payments. These were partly offset by a $265 million increase in net income excluding facility gains.
How is HCA's debt position changing, and is there refinancing risk?
Total debt rose to $40.880 billion from $39.593 billion at year-end 2023. HCA issued $4.5 billion of senior notes in February 2024 and repaid a $2.0 billion note in March. The current portion of long-term debt increased to $4.574 billion, which lowered working capital. About $2.125 billion of debt is variable rate, and a 1% rate increase would reduce annualized pretax earnings by roughly $21 million. Management says cash flow and credit facilities are sufficient for expected liquidity needs.
What is the outlook for capital allocation and shareholder returns?
HCA planned 2024 capital expenditures of $5.1 to $5.3 billion. It repurchased $2.547 billion of stock in the first half and had $4.228 billion of authorization remaining under the January 2024 program. The Board declared a $0.66 quarterly dividend payable September 30, 2024. Share count fell from 265.5 million at year-end 2023 to 259.2 million at June 30, 2024.
Were there any one-time items or risks that affected the reported results?
Results include a $12 million pretax gain on facility sales in Q2 2024 ($0.03 per diluted share). The first half includes a $213 million gain, mainly from the sale of a California hospital. Tax benefits from employee equity settlements were $79 million in the first half, and the effective tax rate rose to 27.4% in Q2 from 24.9%, largely due to unrecognized tax benefit adjustments. Gross unrecognized tax benefits are $711 million, and the IRS is examining 2016 through 2019 returns.
06—Continue